Swedish Orphan Biovitrum biotechnology company opened a new office in Athens, Greece. The launch event started with a ribbon cutting ceremony.
“Our Athens office will enable expanding access to innovative treatments. We aim through close dialogue and cooperation with the Greek authorities to provide high quality care and sustainable access to treatment for people living with rare diseases in Greece,” said Sergio Lai, General Manager Sobi, Italy, Greece, Cyprus and Malta.
Paschalis Apostolides, President of SFEE (Hellenic Association of Pharmaceutical Companies) said:
“We would like to welcome Sobi to Greece and as a future member of SFEE. As a leading international company with know-how in biochemistry and biologic therapies, we are assured that Sobi can provide new and innovative therapeutic solutions for the Greek people.”
“The Greek Haemophilia Society hopes that Sobi’s presence in our country will contribute to providing sustainable access to therapeutic treatments for people with haemophilia and other inherited bleeding disorders,” said Dimitris Verykios, Vice President of the Greek Hemophilia Society.
The ceremony attendees also included: Hege Hellstrom, President Sobi EMENAR; Sergio Lai, General Manager Sobi, Italy, Greece, Cyprus and Malta; and Nicola Zancan, Market Development Director Sobi, Greece, Cyprus and Malta.
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies.